A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Inclusion Criteria:

• Participants with SSc-ILD that have completed Study 218224 through to and includingthe Week 52 visit and are not considered treatment failure, defined as meetingeither of the following criteria:

1. Initiation of new immunosuppressive or immunomodulatory medication forSSc-related disease activity/progression since joining study 218224.

2. Discontinuation of study medication during study 218224 for any reason.

• Participant has an area of uninvolved or mildly thickened skin that, in the opinionof the investigator, would allow subcutaneous (SC) injection at the abdomen or thefront, middle region of the thigh.

• Participant is capable and willing to self-administer the study medication or has acaregiver/healthcare professional who is capable and willing to administer the studymedication throughout the study.

• Female participants: A female participant is eligible to participate if she is notpregnant or breastfeeding, and one of the following conditions applies:

Is a woman of non-childbearing potential (WONCBP) or Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective, with a failure rate of less than (<)1 percentage (%), during the study treatment period and for at least 4 months after the last dose of study intervention. The investigator should evaluate potential for contraceptive method failure (e.g., non-compliance, recently initiated) in relationship to the first dose of study intervention.

1. A WOCBP must have a negative highly sensitive pregnancy test (urine or serum, asrequired by local regulations) within 24 hours before the first dose of studyintervention.

2. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), serumpregnancy test is required. In such cases, the participant must be excluded fromparticipation if the serum pregnancy result is positive.

3. Additional requirements for pregnancy testing during and after study interventionare located.

4. The investigator is responsible for review of medical history, menstrual history,and recent sexual activity to decrease the risk for inclusion of a woman with anearly undetected pregnancy.

• Capable of giving signed informed consent which includes compliance with therequirements and restrictions listed in the informed consent form (ICF) and inthe protocol.

Exclusion Criteria:

• Participants of Study 218224 who have discontinued study treatment, prior to Week

• Participants who have developed clinical evidence of significant, unstable oruncontrolled, acute or chronic diseases not due to SSc (i.e, cardiovascular,pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancyor infectious diseases), or experienced an AE in Study 218224 that could, in theopinion of the principal investigator, put the participant at undue risk.

• Participants who have developed any other medical diseases (eg, cardiopulmonary),laboratory abnormalities, or conditions (eg, poor venous access) that, in theopinion of the investigator could significantly alter the absorption, metabolism, orelimination of drugs; constitutes a risk when taking the study intervention;interferes with the interpretation of data; or it is not safe for the participant tocontinue on the study.

• Participants who have been exposed to ionizing radiation in excess of 10millisievert (mSv) above background over the previous 3 year period as a result ofoccupational exposure or previous participation in research studies.

• QT Interval Corrected (QTc) greater than (>) 480 millisecond (msec) at Week 52 ofparent study 218224 (Day 1 of 219855).